Drug or treatment

Pyrotinib clinical trials

• 39Clinical trials
• 1Country

Newest trials

All recruiting trials (39)

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer

  This study tests a treatment combination of Pyrotinib, Trastuzumab and chemo given before surgery to see if it can improve responses in HER2-positive breast cancer patients who have not yet been treated.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07635342

• Pyrotinib and Trastuzumab with Dalpiciclib vs with Docetaxel in advanced HER2-positive breast cancer

  This study tests whether an oral regimen of pyrotinib + subcutaneous trastuzumab + dalpiciclib works as well as the standard IV regimen with docetaxel in people with advanced HER2-positive breast cancer who have limited prior treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07615751

• Pyrotinib-based regimens for advanced HER2-positive breast cancer: real-world sequential therapy after progression

  This real-world study tests whether giving disitamab vedotin after pyrotinib-based treatment helps people with advanced HER2-positive breast cancer.

  Recruiting Phase 4 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07600164

• Pre-surgery trastuzumab deruxtecan (SHR-A1811) plus pertuzumab for HER2-positive breast cancer

  This trial tests giving trastuzumab deruxtecan (SHR-A1811) with pertuzumab before surgery to see if it helps women with stage II–III HER2-positive breast cancer achieve a complete response.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07393425

• Intensified HER2-targeted treatment for people with a suboptimal response to initial dual HER2 therapy and chemotherapy

  This trial will try stronger targeted drug combinations for people with HER2-positive early breast cancer who don't respond well to initial dual HER2-targeted therapy plus chemotherapy.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07340398

• Using blood ctDNA to compare two pre-surgery HER2-positive breast cancer regimens

  We will test whether two different pre-surgery drug combinations clear tumor DNA from the blood better in people with HER2-positive early breast cancer.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07335081

• Gut bacteria and diarrhea in breast cancer patients on pyrotinib

  This study will see if gut bacteria differ between breast cancer patients on pyrotinib who develop diarrhea and those who don’t, to understand why this side effect happens.

  Recruiting Hubei Cancer Hospital · Wuhan, Hubei · NCT07264985

• Continuous versus intermittent pyrotinib for HER2-positive advanced breast cancer

  This tests whether taking pyrotinib continuously or on an intermittent schedule works better and is safer for adults with HER2-positive advanced breast cancer.

  Recruiting Phase 2 RenJi Hospital · Shanghai · NCT07180082

• RC48 with bevacizumab or pyrotinib for HER2-positive metastatic breast cancer after T-Dxd failure

  This trial will try RC48 together with either bevacizumab or pyrotinib in adults with HER2-positive metastatic breast cancer whose disease has progressed after trastuzumab deruxtecan (T-Dxd).

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07065435

• Pyrotinib + Dalpiciclib + Letrozole for ER-positive, HER2-positive advanced breast cancer

  This trial tests whether combining pyrotinib, dalpiciclib, and letrozole can help people with ER-positive, HER2-positive advanced breast cancer.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07014410

• Evaluating an intelligent management system for medication adherence in breast cancer treatment

  This study is testing a new patient management system to see if it helps women with HER2-positive breast cancer stick to their medication better than usual methods while they receive pyrotinib treatment.

  Recruiting Phase 2/3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06958627

• Combining chemotherapy with pyrotinib and trastuzumab for HER2-positive breast cancer

  This study is testing whether combining chemotherapy with two targeted drugs, pyrotinib and trastuzumab, can help people with HER2-positive breast cancer respond better to treatment before surgery.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou · NCT06832904

• Evaluating Pyrotinib for HER2-positive Advanced Breast Cancer

  This study is testing if a new drug called Pyrotinib, given with standard chemotherapy, can help people with advanced HER2-positive breast cancer feel better and improve their treatment outcomes.

  Recruiting Phase 1 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06770296

• Using pyrotinib and trastuzumab for maintenance therapy in HER2-positive breast cancer

  This study is testing if using the drugs pyrotinib and trastuzumab together can help people with advanced HER2-positive breast cancer stay healthier and prevent brain tumors after their initial treatment.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06754059

• Combining SHR-A1811, Pyrotinib, and Bevacizumab for Advanced Breast Cancer with Brain Metastasis

  This study is testing a new combination of three drugs to see if it can help people with advanced breast cancer that has spread to the brain feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT06718933

• Combining dalpiciclib and pyrotinib for advanced esophageal cancer treatment

  This study is testing if combining two drugs, dalpiciclib and pyrotinib, can help people with advanced esophageal cancer who haven't had success with their first treatment.

  Recruiting Phase 2 Peking University · Beijing, Beijing Municipality · NCT06684600

• Comparing disitamab vedotin and pyrotinib to standard treatment for HER2-positive advanced breast cancer

  This study is testing a new combination of disitamab vedotin and pyrotinib to see if it works better than the standard treatment for people with newly diagnosed HER2-positive advanced breast cancer.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06278870

• Evaluating Pyrotinib dosing for advanced HER2-positive breast cancer

  This study is testing if a lower dose of Pyrotinib is safer and just as effective as the standard dose for people with advanced HER2-positive breast cancer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06254690

• Treatment for locally advanced HER2-positive breast cancer using a combination of drugs

  This study is testing a new combination of drugs to see if it can help women with locally advanced HER2-positive breast cancer get better before surgery.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT06234137

• Combination therapy for HER2-positive breast cancer

  This study is testing a new combination of treatments for women with HER2-positive breast cancer to see if it helps them respond better to therapy before surgery.

  Recruiting First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06035679

• Combining Pyrotinib and Capecitabine for HER2 Positive Early-stage Breast Cancer Treatment

  This study is testing if combining two drugs, Pyrotinib and Capecitabine, can help women with early-stage HER2 positive breast cancer after surgery feel better compared to other treatments their doctors choose.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06035016

• Combining Disitamb Vedotin and Pyrotinib for HER2-positive Early Breast Cancer

  This study is testing if combining two drugs, Disitamb Vedotin and pyrotinib, can help people with early HER2-positive breast cancer who haven't had treatment before.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06001086

• Neoadjuvant treatment for ER+/HER2+ breast cancer using a combination of drugs

  This study is testing a new combination of drugs to see if it helps women with early or locally advanced HER2-positive breast cancer shrink their tumors before surgery.

  Recruiting at 2 sites Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei and 1 other locations · NCT06000917

• Comparing continuous and intermittent use of pyrotinib for HER2-positive breast cancer

  This study is testing whether taking the cancer drug pyrotinib continuously or in intervals helps people with HER2-positive breast cancer do better and feel less side effects after their initial treatment.

  Recruiting Phase 3 RenJi Hospital · Shanghai · NCT05910398

• Combining Pyrotinib and Capecitabine for Early HER2 Positive Breast Cancer

  This study is testing if combining two medications, pyrotinib and capecitabine, can help women with early-stage HER2-positive breast cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05861271

• Combining inetetamab, pyrotinib, and vinorelbine for treating advanced HER2-positive breast cancer

  This study is testing a new combination of three drugs to see if they can help people with advanced HER2-positive breast cancer feel better and live longer.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT05856383

• Using Pyrotinib to Reduce Recurrence Risk in Early Stage HER2-positive Breast Cancer

  This study is testing if the drug pyrotinib can help reduce the chances of breast cancer coming back in women with early stage HER2-positive breast cancer who haven't fully responded to previous treatments.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05834764

• Using pyrotinib to treat advanced HER2-positive non-small cell lung cancer

  This study is testing if a new drug called pyrotinib can help people with advanced HER2-positive non-small cell lung cancer feel better as a first treatment option.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT05751018

• Combination treatment for HR+/HER2+ breast cancer

  This study is testing a new combination treatment for patients with stage II-III HR+/HER2+ breast cancer to see if it works better than the standard treatment before surgery.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT05638594

• Neoadjuvant treatment for HER2-positive breast cancer using SHR-A1811 and pyrotinib

  This study is testing a new combination of two drugs, SHR-A1811 and pyrotinib, to see if they can help people with Stage II-III HER2-positive breast cancer before surgery.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT05635487

• Combining GQ1001 and Pyrotinib for HER2 Positive Metastatic Breast Cancer

  This study is testing a new combination of two drugs, GQ1001 and pyrotinib, to see if it helps people with HER2-positive metastatic breast cancer who haven't had success with other treatments.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT05575804

• Injectable SHR-A1811 with Pyrotinib or SHR-1316 for advanced lung cancer

  This study is testing if a new injectable treatment called SHR-A1811, used with either Pyrotinib or SHR-1316, can help people with advanced lung cancer that has a specific marker called HER2.

  Recruiting at 2 sites Phase 1/2 Jiangsu HengRui Medicine Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT05482568

• Comparing targeted therapies for HER2 positive early breast cancer after surgery

  This study is testing whether a new combination of treatments can help women with HER2 positive early breast cancer do better after surgery compared to sticking with their original therapy.

  Recruiting Phase 2 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT05292742

• Combination treatment for stage II-III triple-positive breast cancer

  This study is testing a new combination treatment for women with stage II-III triple-positive breast cancer to see if it helps shrink tumors before surgery.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT05228951

• Combining Pyrotinib and ARX788 for treating HER2-positive breast cancer

  This study is testing a new combination of two drugs, pyrotinib and ARX788, to see if it can help women with stage II-III HER2-positive breast cancer who haven't responded well to other treatments.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT04983121

• Combination of Fulvestrant and Pyrotinib for Advanced Breast Cancer

  This study is testing if a new combination of fulvestrant and pyrotinib can help people with advanced breast cancer feel better and have fewer side effects than the standard treatment.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT04646759

• Using pyrotinib to prevent recurrence in HER-2 positive breast cancer

  This study is testing if the drug pyrotinib can help prevent breast cancer from coming back in women who have already been treated for HER2-positive breast cancer.

  Recruiting Phase 3 RenJi Hospital · Shanghai, Shanghai Municipality · NCT04254263

Quick answers

How many clinical trials of Pyrotinib are recruiting right now?

39, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 20, Phase 3: 6, Phase 1/2: 4, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →